Acta Veterinaria et Zootechnica Sinica ›› 2025, Vol. 56 ›› Issue (6): 2836-2846.doi: 10.11843/j.issn.0366-6964.2025.06.027

• Preventive Veterinary Medicine • Previous Articles     Next Articles

Prokaryotic Expression and Analysis of Bacteriostatic Effects of Porcine β-defensin-1

GUO Deyang1(), HU Hui1(), ZHENG Xueli2,*(), JIANG Yanfen1,*()   

  1. 1. College of Veterinary Medicine, Northwest A & F University, Xianyang 712100, China
    2. College of Forestry, Northwest A & F University, Xianyang 712100, China
  • Received:2024-05-27 Online:2025-06-23 Published:2025-06-25
  • Contact: ZHENG Xueli, JIANG Yanfen E-mail:1969415294@qq.com;huihu_66@163.com;zhengxueli@nwafu.edu.cn;jyf1111@nwafu.edu.cn

Abstract:

The aim of this study was to investigate the antibacterial activity in vivo and in vitro of PBD-1 over-expressed by prokaryotes, and to provide material and theoretical basis for the treatment of clinical mastitis. In this study, prokaryotic expression vectors of PBD-1 were constructed, the induced expression conditions were optimized, the minimum inhibitory concentration (MIC) was determined after over-expression and purification, and the bactericidal dynamic curve was drawn. The mouse model of mastitis was established with E. coli13-1 and S. aureus 4-1, and the intramammary perfusion therapy was performed with different concentrations of PBD-1, and the therapeutic effect was observed through the pathological changes of breast tissue and its bacterial load. The results showed that the prokaryotic expression vector of PBD-1 was successfully constructed, the recombinant PBD-1 was soluble and yielded of 328.6 mg·mL-1. The recombinant PBD-1 had antibacterial effect on E. coli 13-1, S. aureus 4-1 and S. epidermidis 25-1, and the MIC was 82.15 μg·mL-1 in vitro. The results of intramammary perfusion test showed that PBD-1 with 1×MIC and 2×MIC had a certain therapeutic effect on S. aureus 4-1 andE. coli 13-1 mouse mastitis models. Prokaryotic expression of recombinant PBD-1 has inhibitory effects on all three detected bacteriain vitro, and has therapeutic effects on S. aureus4-1 and E. coli 13-1 mastitis models.

Key words: prokaryotic expression, mastitis, PBD-1, antibacterial activity in vitro, animal model

CLC Number: